目的 探究基于一体化护理管理模式下高压氧联合新辅助化疗对口腔癌患者临床疗效及预后复发的影响。 方法 收集2017年3月至2020年12月首都医科大学附属北京同仁医院确诊为口腔癌患者100例作为研究对象。按照随机数字表法分为对照组和联合组，每组50例。对照组在基于一体化护理管理模式下联合新辅助化疗方案进行干预，联合组在对照组治疗的基础上予以高压氧治疗。采用酶联免疫吸附法检测患者血清肿瘤坏死因子-α（TNF-α）、白细胞介素（IL）-2、IL-6的表达水平；采用流式细胞术检测患者外周血CD3、CD4、CD8的百分比；采用实体瘤疗效评价标准评价口腔癌患者的临床疗效，并统计患者治疗过程中不良反应及复发率。 结果 联合组治疗总有效率（60.0%）明显高于对照组（40.0%），联合组患者不良反应发生率（38.0%）明显高于对照组（20.0%），联合组患者治疗后2年内复发率（14.0%）明显低于对照组（26.0%），差异均有统计学意义（P<0.05）。联合组患者治疗后血清TNF-α、IL-2、IL-6水平明显低于对照组（P<0.01）。联合组患者治疗后外周血CD3、CD4百分比明显高于对照组，CD8百分比明显低于对照组（P<0.05）。 结论 基于一体化管理模式下采用高压氧联合新辅助化疗能提高口腔癌患者的治疗依从性，增强机体的免疫功能，对减少口腔癌患者不良反应及预后复发具有较好的作用。 Objective To study the clinical efficacy of hyperbaric oxygen combined with neoadjuvant chemotherapy on patients with oral cancer and its influence on recurrence based on integrated nursing management model. Methods A total of 100 patients diagnosed as oral cancer in Beijing Tongren Hospital affiliated to Capital Medical University from March 2017 to December 2020 were collected as the research subjects and divided into control group and combination group according to the random number table method，with 50 cases in each group. The control group was received neoadjuvant chemotherapy based on the integrated nursing management model，and the combination group was given hyperbaric oxygen therapy on the basis of the treatment of the control group. Enzyme-linked immunosorbent assay was used to detect the expression levels of tumor necrosis factor-α（TNF-α），interleukin-2（IL-2），and interleukin-6（IL-6）；flow cytometry was conducted to detect the proportion of CD3，CD4，and CD8 in peripheral blood of the patients. Response Evaluation Criteria in Solid Tumors（RECIST）was applied to evaluate the efficacy on the patients with oral cancer，and the incidence of adverse reactions during the treatment was also recorded. Results The total effective rate of the combination group（60.0%）was significantly higher than that of the control group（40.0%）；the incidence of adverse reactions in the combination group（38.0%）was significantly higher than that in the control group（20.0%）；the recurrence rate within two years after treatment in the combination group（14.0%）was significantly lower than that in the control group（26.0%），all differences were statistically significant（P<0.05）. After treatment，the serum levels of TNF-α，IL-2，and IL-6 in the combination group were significantly lower than those in the control group（P<0.01），and the proportions of CD3 and CD4 in the peripheral blood in the combination group were significantly higher than those in the control group，but the proportion of CD8 was significantly lower than that in the control group（P<0.05）. Conclusion Based on integrated management nursing model，hyperbaric oxygen combined with neoadjuvant chemotherapy can improve the treatment compliance in patients with oral cancer and enhance the immune function of the body，which has a good effect on reducing the incidence and recurrence rate of adverse reactions of the patients with oral cancer.
Clinical efficacy of hyperbaric oxygen combined with neoadjuvant chemotherapy on patients with oral cancer and its influence on recurrence based on integrated nursing management model
Objective To study the clinical efficacy of hyperbaric oxygen combined with neoadjuvant chemotherapy on patients with oral cancer and its influence on recurrence based on integrated nursing management model. Methods A total of 100 patients diagnosed as oral cancer in Beijing Tongren Hospital affiliated to Capital Medical University from March 2017 to December 2020 were collected as the research subjects and divided into control group and combination group according to the random number table method，with 50 cases in each group. The control group was received neoadjuvant chemotherapy based on the integrated nursing management model，and the combination group was given hyperbaric oxygen therapy on the basis of the treatment of the control group. Enzyme-linked immunosorbent assay was used to detect the expression levels of tumor necrosis factor-α（TNF-α），interleukin-2（IL-2），and interleukin-6（IL-6）；flow cytometry was conducted to detect the proportion of CD3，CD4，and CD8 in peripheral blood of the patients. Response Evaluation Criteria in Solid Tumors（RECIST）was applied to evaluate the efficacy on the patients with oral cancer，and the incidence of adverse reactions during the treatment was also recorded. Results The total effective rate of the combination group（60.0%）was significantly higher than that of the control group（40.0%）；the incidence of adverse reactions in the combination group（38.0%）was significantly higher than that in the control group（20.0%）；the recurrence rate within two years after treatment in the combination group（14.0%）was significantly lower than that in the control group（26.0%），all differences were statistically significant（P<0.05）. After treatment，the serum levels of TNF-α，IL-2，and IL-6 in the combination group were significantly lower than those in the control group（P<0.01），and the proportions of CD3 and CD4 in the peripheral blood in the combination group were significantly higher than those in the control group，but the proportion of CD8 was significantly lower than that in the control group（P<0.05）. Conclusion Based on integrated management nursing model，hyperbaric oxygen combined with neoadjuvant chemotherapy can improve the treatment compliance in patients with oral cancer and enhance the immune function of the body，which has a good effect on reducing the incidence and recurrence rate of adverse reactions of the patients with oral cancer.
万方数据
